secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001601485-25-000123
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events
--------------------------------------------------------------------------------

- Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.
- Raised ~$11.1M gross via ATM since Q3 start; cash $20.6M at Sep 30, extending runway through Q2 2026.
- Q3 net loss $10.1M ($0.60/sh) vs $18.8M ($1.39) YoY; R&D expense down to $5.0M from $7.2M.
- IDMC recommended continue Phase 2 without modifications; after DFS analysis, will request End of Phase 2 FDA meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/0001601485-25-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/angn-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer